Pharma Pioneer

Preliminary Phase 1/2 Clinical Trial Results for mRNA-3927, a Potential mRNA Treatment for Propionic Acidemia, Featured in Nature Journal

17 May 2024
2 min read

Moderna, a biotechnology company, has reported preliminary results from a phase 1/2 clinical trial for mRNA-3927, an experimental treatment for propionic acidemia (PA), a rare genetic metabolic disorder. The study, published in Nature, showed that mRNA-3927 was well-tolerated with few side effects and demonstrated a reduction in the frequency of metabolic decompensation events (MDEs) in patients. Kyle Holen, Moderna's Senior Vice President, highlighted the significance of these findings, especially considering the lack of approved treatments for PA.
The trial, registered with the identifier NCT04159103, included participants over one year old with genetically confirmed PA. As of May 31, 2023, 16 participants had received mRNA-3927, with 12 continuing into an extension study after completing the trial. Over 340 doses were administered, equating to more than 15 person-years of treatment. The therapy was found to be safe, with no dose-limiting toxicities observed, and a 70% reduction in the risk of MDEs during the treatment period.
PA is a serious condition that affects approximately one in every 100,000 to 150,000 people globally, caused by mutations in the PCCA and PCCB genes, leading to a deficiency in the propionyl-CoA carboxylase enzyme. This deficiency results in the accumulation of toxic metabolites, causing MDEs and a range of multisystemic complications, including neurological issues and heart problems.
mRNA-3927 is an innovative mRNA therapy delivered intravenously and encapsulated in lipid nanoparticles. It encodes for the PCCA and PCCB subunits to restore the functionality of the deficient PCC enzyme in the liver, potentially replacing the missing or nonfunctional enzyme.
Moderna is a pioneer in mRNA medicine, known for its rapid development of medicines, including a highly effective COVID-19 vaccine. The company's mRNA platform is also being used to develop treatments for various diseases, from infectious to autoimmune conditions. Moderna's commitment to mRNA medicines aims to significantly impact human health.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Achilles Therapeutics Reports Interim Phase I/IIa Results for Clonal Neoantigen T Cells in NSCLC and Melanoma with Enhanced Conditioning
Pharma Pioneer
3 min read
Achilles Therapeutics Reports Interim Phase I/IIa Results for Clonal Neoantigen T Cells in NSCLC and Melanoma with Enhanced Conditioning
17 May 2024
Achilles Therapeutics plc has reported interim Phase I/IIa clinical trial data for clonal neoantigen reactive T cells (cNeT) from the CHIRON study for non-small cell lung cancer (NSCLC) and the THETIS study for malignant melanoma
Read →
CureVac Reveals Positive Interim Phase 2 Results for Seasonal Flu Vaccine in Partnership with GSK
Pharma Pioneer
3 min read
CureVac Reveals Positive Interim Phase 2 Results for Seasonal Flu Vaccine in Partnership with GSK
17 May 2024
This innovative vaccine, developed by CureVac, is multivalent and contains antigens that match the four flu strains recommended by the World Health Organization (WHO).
Read →
Eilean Therapeutics Granted Approval to Launch Phase I R/R AML Clinical Trial Utilizing Lomonitinib, a Targeted FLT3/IRAK4 Inhibitor
Pharma Pioneer
2 min read
Eilean Therapeutics Granted Approval to Launch Phase I R/R AML Clinical Trial Utilizing Lomonitinib, a Targeted FLT3/IRAK4 Inhibitor
17 May 2024
Eilean Therapeutics LLC has received approval from the Human Research Ethics Committee in Australia to commence a Phase I clinical trial for lomonitinib (ZE46-0134).
Read →
International Wound Journal Publishes Microbion's Phase 1b Study on Pravibismane for Treating Diabetic Foot Ulcer Infections
Pharma Pioneer
3 min read
International Wound Journal Publishes Microbion's Phase 1b Study on Pravibismane for Treating Diabetic Foot Ulcer Infections
17 May 2024
A recent Phase 1b clinical trial of topical pravibismane for managing moderate to severe diabetic foot ulcers has shown promising results.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.